NO20052026L - Anvendelse av (R)-verapamil for behandlingen av unormale okninger i gastrointestinal bevegelighet - Google Patents

Anvendelse av (R)-verapamil for behandlingen av unormale okninger i gastrointestinal bevegelighet

Info

Publication number
NO20052026L
NO20052026L NO20052026A NO20052026A NO20052026L NO 20052026 L NO20052026 L NO 20052026L NO 20052026 A NO20052026 A NO 20052026A NO 20052026 A NO20052026 A NO 20052026A NO 20052026 L NO20052026 L NO 20052026L
Authority
NO
Norway
Prior art keywords
verapamil
gastrointestinal motility
treatment
abnormal increases
conditions
Prior art date
Application number
NO20052026A
Other languages
English (en)
Inventor
John G Devane
John Kelly
Original Assignee
Agi Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Ltd filed Critical Agi Therapeutics Ltd
Publication of NO20052026L publication Critical patent/NO20052026L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfirmelsen er rettet mot fremgangsmåter for behandling, forebygging og/eller håndtering av unormale økninger i gastiointestinal bevegelighet og tarmtilstander som forårsaker dette. Slike tilstander inkluderer, men er ikke begrenset til, irritabelt tarmsyndrom (IBS), infeksiøse sykdommer i tyrm- og tykktarmen og symptomer på en hvilken som helst av de foregående tilstandene. Spesielt angår oppfirmelsen fremgangsmåter for anvendelse beriket (R)verapamil så vel som sammensetninger og formuleringer som irmeholder dette.
NO20052026A 2002-09-27 2005-04-26 Anvendelse av (R)-verapamil for behandlingen av unormale okninger i gastrointestinal bevegelighet NO20052026L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/256,261 US20030092765A1 (en) 2001-11-15 2002-09-27 Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil
PCT/IB2002/005140 WO2004032919A1 (en) 2002-09-27 2002-11-15 Use of (r)-verapamil for the treatment of abnormal increases in gastrointestinal motility

Publications (1)

Publication Number Publication Date
NO20052026L true NO20052026L (no) 2005-04-26

Family

ID=32029241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052026A NO20052026L (no) 2002-09-27 2005-04-26 Anvendelse av (R)-verapamil for behandlingen av unormale okninger i gastrointestinal bevegelighet

Country Status (10)

Country Link
US (2) US20030092765A1 (no)
EP (2) EP1891947A3 (no)
JP (1) JP2006504724A (no)
AU (1) AU2002351118B2 (no)
CA (1) CA2499290A1 (no)
MX (1) MXPA05003177A (no)
NO (1) NO20052026L (no)
NZ (1) NZ539059A (no)
WO (1) WO2004032919A1 (no)
ZA (1) ZA200502306B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060233873A1 (en) * 2003-01-24 2006-10-19 Julien Meissonnier Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US8486381B2 (en) * 2005-09-02 2013-07-16 Amgen Inc. Methods of modulating intestinal fluid balance
AU2007293107A1 (en) * 2006-08-04 2008-03-13 Agi Therapeutics Research Limited Methods for treating at least one condition having MT1 receptor, 5HT2GB receptor, and L-type calcium channel activity
CA2681582C (en) * 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
US20090023814A1 (en) * 2007-07-18 2009-01-22 Agi Therapeutics Research Ltd. Compositions and methods having mt1 receptor activity
MX2011006307A (es) * 2008-12-15 2011-10-14 Banner Pharmacaps Inc Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.
US20110301245A1 (en) * 2010-06-04 2011-12-08 Agi Therapeutics, Plc (r)-2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril formulaitons, andthe use of such formulations in the treatment of conditions mediated by the serotonin transporter
US20170119680A1 (en) 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
BR112018073688A2 (pt) * 2016-05-20 2019-02-26 Center Laboratories, Inc. método de tratamento de hiperglicemia
EP3509572A4 (en) * 2016-09-08 2020-05-13 Synergistic Therapeutics, LLC TOPICAL FORMULATION FOR HAIR GROWTH

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3635931A1 (de) * 1986-10-22 1988-04-28 Basf Ag Wirkstoffe zur verhuetung von tumormetastasen
US6190691B1 (en) * 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5910601A (en) 1994-09-26 1999-06-08 Darwin Discovery Limited Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5892093A (en) 1996-02-08 1999-04-06 Darwin Discovery Limited Resolution
GB9605074D0 (en) 1996-03-11 1996-05-08 Chiroscience Ltd Dosage forms and uses
WO1997044025A1 (en) 1996-05-23 1997-11-27 G.D. Searle & Co. Pharmaceutical compositions containing non-racemic verapamil and process for optimizing the pharmaceutical activity of r- and s-verapamil
GB9616549D0 (en) 1996-08-06 1996-09-25 Chiroscience Ltd Therapeutic product and its use
AU3778497A (en) 1996-08-06 1998-02-25 Darwin Discovery Limited Therapeutic utilities of verapamil enantiomers
GB9616504D0 (en) 1996-08-06 1996-09-25 Chiroscience Ltd Therapeutic product and its use

Also Published As

Publication number Publication date
AU2002351118A1 (en) 2004-05-04
AU2002351118B2 (en) 2009-03-12
CA2499290A1 (en) 2004-04-22
MXPA05003177A (es) 2005-11-23
WO2004032919A1 (en) 2004-04-22
ZA200502306B (en) 2006-12-27
EP1891947A3 (en) 2008-03-05
EP1542673A1 (en) 2005-06-22
NZ539059A (en) 2006-10-27
US6849661B2 (en) 2005-02-01
US20040063784A1 (en) 2004-04-01
US20030092765A1 (en) 2003-05-15
JP2006504724A (ja) 2006-02-09
EP1891947A2 (en) 2008-02-27

Similar Documents

Publication Publication Date Title
NO20052026L (no) Anvendelse av (R)-verapamil for behandlingen av unormale okninger i gastrointestinal bevegelighet
NO20073764L (no) Sammensetninger for behandling av HCV
NO20061911L (no) Immunogene sammensetninger
NO20081086L (no) Makrosykliske peptider som HCV NS3-proteaseinhibitorer
NO20052348L (no) Behandling av hemoragisk sjokk
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
NO20092053L (no) HCV NS3-proteaseinhibitorer
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
EA200700336A1 (ru) Противовирусные соединения
NO20072286L (no) Hemming av HCV NS3-NS4A-protease
NO20044808L (no) Heterosykliske sulfonamider som er hepatitt C virus inhibitorer
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
IS7533A (is) Lifrarbólgu C-veirutálmar
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
NO20044658L (no) Anvendelse av osteoprotegerin til behandling og/eller forhindring av fibrotiske sykdommer
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
EA200701297A1 (ru) Соединения пиридазинона
NO20065320L (no) Imidazolderivater anvendt som tafiainhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application